Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

Acute stroke management in patients with known or suspected atrial fibrillation.

Mandzia JL, Hill MD.

Can J Cardiol. 2013 Jul;29(7 Suppl):S45-53. doi: 10.1016/j.cjca.2013.04.031. Review.

PMID:
23790598
2.

Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).

Patel MR, Hellkamp AS, Lokhnygina Y, Piccini JP, Zhang Z, Mohanty S, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Becker RC, Nessel CC, Berkowitz SD, Califf RM, Fox KA, Mahaffey KW.

J Am Coll Cardiol. 2013 Feb 12;61(6):651-8. doi: 10.1016/j.jacc.2012.09.057.

3.

Novel oral anticoagulants for stroke prevention in atrial fibrillation: key trial findings and clinical implications.

Goette A.

Trends Cardiovasc Med. 2013 May;23(4):128-34. doi: 10.1016/j.tcm.2012.10.001. Epub 2013 Jan 11. Review.

PMID:
23313169
4.

New oral anticoagulants in non-valvular atrial fibrillation.

Francia P, Adduci C, Santini D, Musumeci B, Tocci G.

High Blood Press Cardiovasc Prev. 2013 Jun;20(2):53-60. doi: 10.1007/s40292-013-0011-6. Epub 2013 May 8. Review.

PMID:
23653173
5.

Novel oral anticoagulants in atrial fibrillation: a meta-analysis of large, randomized, controlled trials vs warfarin.

Dogliotti A, Paolasso E, Giugliano RP.

Clin Cardiol. 2013 Feb;36(2):61-7. doi: 10.1002/clc.22081. Epub 2013 Jan 21. Review.

6.

Effectiveness and safety of warfarin initiation in older hemodialysis patients with incident atrial fibrillation.

Winkelmayer WC, Liu J, Setoguchi S, Choudhry NK.

Clin J Am Soc Nephrol. 2011 Nov;6(11):2662-8. doi: 10.2215/CJN.04550511. Epub 2011 Sep 29.

7.

Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.

Hylek EM, Go AS, Chang Y, Jensvold NG, Henault LE, Selby JV, Singer DE.

N Engl J Med. 2003 Sep 11;349(11):1019-26.

8.

Periprocedural management of oral anticoagulation in patients with atrial fibrillation: approach in the era of new oral anticoagulants.

Healey JS, Brambatti M.

Can J Cardiol. 2013 Jul;29(7 Suppl):S54-9. doi: 10.1016/j.cjca.2013.02.021. Review.

PMID:
23790599
9.

An update on antithrombotic therapy in atrial fibrillation: the role of newer and emergent drugs.

Deedwania P, Huang GW.

Rev Cardiovasc Med. 2012;13(2-3):e89-104. Review.

PMID:
23160166
10.

Stroke prevention in atrial fibrillation patients with chronic kidney disease.

Hart RG, Eikelboom JW, Brimble KS, McMurtry MS, Ingram AJ.

Can J Cardiol. 2013 Jul;29(7 Suppl):S71-8. doi: 10.1016/j.cjca.2013.04.005. Review.

PMID:
23790601
11.

Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.

Freeman JV, Zhu RP, Owens DK, Garber AM, Hutton DW, Go AS, Wang PJ, Turakhia MP.

Ann Intern Med. 2011 Jan 4;154(1):1-11. doi: 10.7326/0003-4819-154-1-201101040-00289. Epub 2010 Nov 1.

PMID:
21041570
12.

Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.

Potpara TS, Polovina MM, Licina MM, Stojanovic RM, Prostran MS, Lip GY.

Adv Ther. 2012 Jun;29(6):491-507. doi: 10.1007/s12325-012-0026-8. Epub 2012 Jun 7. Review.

PMID:
22684583
13.

Atrial fibrillation and anticoagulation therapy: different race, different risk, and different management?

Vivas D, Olmos C, Vilacosta I.

Circ J. 2011;75(6):1314-5. Epub 2011 Apr 29. No abstract available.

14.

Anticoagulation for atrial fibrillation: state of the art and recommendations for a quickly moving target.

Nattel S, Cairns J, Healey JS, Talajic M.

Can J Cardiol. 2013 Jul;29(7 Suppl):S1-3. doi: 10.1016/j.cjca.2013.05.001. No abstract available.

PMID:
23790593
15.

Predictors of warfarin use in atrial fibrillation patients in the inpatient setting.

Agarwal S, Bennett D, Smith DJ.

Am J Cardiovasc Drugs. 2010;10(1):37-48. doi: 10.2165/11318870-000000000-00000.

PMID:
20104933
16.

Novel oral anticoagulants for stroke prevention in atrial fibrillation: results of the European Heart Rhythm Association survey.

Lip GY, Bongiorni MG, Dobreanu D, Lewalter T, Hastrup Svendsen J, Blomström-Lundqvist C; Scientific Initiative Committee, European Heart Rhythm Association.

Europace. 2013 Oct;15(10):1526-32. doi: 10.1093/europace/eut292.

PMID:
24072770
17.

[Cardioembolic stroke in atrial fibrillation and new anticoagulation criteria: a therapeutic dare].

Perez-Ortega I, Moniche-Alvarez F, Jimenez-Hernandez MD, Gonzalez-Marcos JR.

Rev Neurol. 2012 Jul 16;55(2):74-80. Spanish.

18.

Old and new oral anticoagulants for venous thromboembolism and atrial fibrillation: a review of the literature.

Becattini C, Vedovati MC, Agnelli G.

Thromb Res. 2012 Mar;129(3):392-400. doi: 10.1016/j.thromres.2011.12.014. Epub 2012 Jan 20. Review.

PMID:
22264937
19.

Variability of INR and its relationship with mortality, stroke, bleeding and hospitalisations in patients with atrial fibrillation.

Lind M, Fahlén M, Kosiborod M, Eliasson B, Odén A.

Thromb Res. 2012 Jan;129(1):32-5. doi: 10.1016/j.thromres.2011.07.004. Epub 2011 Aug 17.

PMID:
21851969
20.

Present status of anticoagulation treatment in Japanese patients with atrial fibrillation: a report from the J-RHYTHM Registry.

Atarashi H, Inoue H, Okumura K, Yamashita T, Kumagai N, Origasa H; J-RHYTHM Registry Investigators.

Circ J. 2011;75(6):1328-33. Epub 2011 Apr 5.

Supplemental Content

Support Center